Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ophthalmic metformin - Curative Biotechnology/National Institutes of Health

Next Previous
Drug Profile

Ophthalmic metformin - Curative Biotechnology/National Institutes of Health

Latest Information Update: 10 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Curative Biotechnology
  • Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
  • Mechanism of Action Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Age-related macular degeneration
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Age-related macular degeneration
  • No development reported Choroideraemia; Diabetic retinopathy; Retinal disorders; Retinitis pigmentosa; Stargardt disease

Most Recent Events

  • 10 Sep 2025 Ophthalmic metformin is still in preclinical trials for Age-related macular degeneration in USA (Ophthalmic) (Curative Biotechnology pipeline, September 2025)
  • 28 Jun 2025 No recent reports of development identified for preclinical development in Choroideraemia in USA (Ophthalmic)
  • 28 Jun 2025 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (Ophthalmic)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top